Article Text

Download PDFPDF

Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease
  1. Ambrogio Orlando1,
  2. Rosalba Orlando1,
  3. Francesco Ciccia2,
  4. Sara Renna1,
  5. Aroldo Rizzo3,
  6. Mario Cottone1,
  7. Fabio Salvatore Macaluso1
  1. 1 Division of Internal Medicine, “Villa Sofia-Cervello” Hospital, Palermo, Italy
  2. 2 Di.Bi.M.I.S., Section of Rheumatology, University of Palermo, Palermo, Italy
  3. 3 Department of Pathology, “Villa Sofia-Cervello” Hospital, Palermo, Italy
  1. Correspondence to Dr Ambrogio Orlando, Division of Internal Medicine, “Villa Sofia-V. Cervello” Hospital, Palermo 90146, Italy; ambrogiorlando{at}

Statistics from

Vedolizumab (VDZ) is a new biological agent which was recently approved for the treatment of inflammatory bowel disease (IBD)1 following the good clinical responses reported by clinical trials for both Crohn's disease2 and ulcerative colitis.3 However, the effects of VDZ on extraintestinal manifestations were not reported in these trials, and the ‘real life’ experience is still limited. On these premises, we read with interest the recent work by Varkas et al 4 reporting a series of five patients with IBD who were treated with VDZ and promptly developed new onset or exacerbation of spondyloarthritis (SpA), irrespective of the response to treatment on intestinal symptoms. Although the hypotheses proposed …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles